Inhibition of Chemokine Receptor CCR2 and CCR5 Expression Contributes to Simvastatin-induced Attenuation of Cardiac Allograft Vasculopathy

Journal of Heart and Lung Transplantation

Volumn 26, Issue 5, 2007, Pages 485-493

  Yin, Rong ^a   Zhu, Jiaquan ^a   Shao, Hongtao ^a   Cheng, Xiaofeng ^a   Feng, Xiaomei ^a   Li, Zhongdong ^a   Jing, Hua ^a  

^a JINLING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN A; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SIMVASTATIN;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT RECIPIENT; HEART; HEART TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; ISOGRAFT; LOW DRUG DOSE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANIMALS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; MALE; RANDOM ALLOCATION; RANTES; RATS; RATS, INBRED F344; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SIMVASTATIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 34247118724     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.02.006     Document Type: Article

References (34)

1. Ramzy D., Rao V., Brahm J., Miriuka S., Delgado D., and Ross H.J. Cardiac allograft vasculopathy: a review. Can J Surg 48 (2005) 319-327
2. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report-2002. J Heart Lung Transplant 21 (2002) 950-970
3. Vassalli G., Gallino A., Weis M., et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 24 (2003) 1180-1188
4. Hancock W.W. Chemokine receptor-dependent alloresponses. Immunol Rev 196 (2003) 37-50
5. Nelson P.J., and Krensky A.M. Chemokines, chemokine receptors, and allograft rejection. Immunity 14 (2001) 377-386
6. Hancock W.W., Wang L., Ye Q., Han R., and Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 15 (2003) 479-486
7. Horiguchi K., Kitagawa-Sakakida S., Sawa Y., et al. Selective chemokine and receptor gene expressions in allografts that develop transplant vasculopathy. J Heart Lung Transplant 21 (2002) 1090-1100
8. Hancock W.W., Lu B., Gao W., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192 (2000) 1515-1520
9. Jiankuo M., Xingbing W., Baojun H., et al. Peptide nucleic acid antisense prolongs skin allograft survival by means of blockade of CXCR3 expression directing T cells into graft. J Immunol 170 (2003) 1556-1565
10. Gao W., Faia K.L., Csizmadia V., et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 72 (2001) 1199-1205
11. Akashi S., Sho M., Kashizuka H., et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 80 (2005) 378-384
12. Yun J.J., Whiting D., Fischbein M.P., et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 109 (2004) 932-937
13. Maggard M.A., Ke B., Wang T., et al. Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 65 (1998) 149-155
14. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 suppl 1 (2004) III-39-43
15. Shimizu K., Aikawa M., Takayama K., Libby P., and Mitchell R.N. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108 (2003) 2113-2120
16. Veillard N.R., Braunersreuther V., Arnaud C., et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188 (2006) 51-58
17. Fujino M., Miura S., Matsuo Y., Tanigawa H., Kawamura A., and Saku K. Pitavastatin-induced downregulation of CCR2 and CCR5 in monocytes is associated with the arrest of cell-cycle in S phase. Atherosclerosis 187 (2006) 301-308
18. Adams D.H., Tilney N.L., Collins Jr. J.J., and Karnovsky M.J. Experimental graft arteriosclerosis. I. The Lewis-to-F-344 allograft model. Transplantation 53 (1992) 1115-1119
19. Ono K., and Lindsey E.S. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 57 (1969) 225-229
20. Fischbein M.P., Yun J., Laks H., et al. Regulated interleukin-10 expression prevents chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg 126 (2003) 216-223
21. Li Y., Koster T., Morike C., et al. Pravastatin prolongs graft survival in an allogeneic rat model of orthotopic single lung transplantation. Eur J Cardiothorac Surg 30 (2006) 515-524
22. Ji P., Si M.S., Podnos Y., Chow H., Steward E., and Imagawa D.K. Prevention of chronic rejection by pravastatin in a rat kidney transplant model. Transplantation 74 (2002) 821-827
23. Arita S., Kasraie A., Une S., Ohtsuka S., Smith C.V., and Mullen Y. Prolongation of islet allograft survival in mice by combined treatment with pravastatin and low-dose cyclosporine. Cell Transplant 10 (2001) 639-644
24. Gregory C.R., Katznelson S., Griffey S.M., Kyles A.E., and Berryman E.R. Fluvastatin in combination with RAD significantly reduces graft vascular disease in rat cardiac allografts. Transplantation 72 (2001) 989-993
25. Dechend R., Gieffers J., Dietz R., et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 108 (2003) 261-265
26. Han K.H., Ryu J., Hong K.H., et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 111 (2005) 1439-1447
27. Rollins B.J. Chemokines. Blood 90 (1997) 909-928
28. Russell M.E., Adams D.H., Wyner L.R., Yamashita Y., Halnon N.J., and Karnovsky M.J. Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci USA 90 (1993) 6086-6090
29. Melter M., Exeni A., Reinders M.E., et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 104 (2001) 2558-2564
30. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., and Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193 (2001) 975-980
31. Yun J.J., Fischbein M.P., Laks H., et al. Early and late chemokine production correlates with cellular recruitment in cardiac allograft vasculopathy. Transplantation 69 (2000) 2515-2524
32. Ortego M., Bustos C., Hernandez-Presa M.A., et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147 (1999) 253-261
33. Waehre T., Damas J.K., Gullestad L., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41 (2003) 1460-1467
34. Kapoor A., Morita K., Engeman T.M., et al. Early expression of interferon-gamma inducible protein 10 and monokine induced by interferon-gamma in cardiac allografts is mediated by CD8+ T cells. Transplantation 69 (2000) 1147-1155